Insights on PARP Inhibition and Ovarian Cancer - priME Oncology

Insights on PARP Inhibition and Ovarian Cancer

Leading the Field in Exploiting DNA Repair as a Therapeutic Target

Not a member of My prIME? Join now for instant access.

Enhance your understanding of the use of PARP inhibitors in ovarian cancer with videos from our satellite symposium at the 20th International Meeting of the European Society of Gynaecological Oncology. A variety of topics will be discussed, including DNA repair and PARP inhibition, use of PARP inhibitors in various settings, practical considerations for PARP inhibitor therapy in the clinic, and future directions.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



1.0 AMA PRA Category 1 Credit™

Release Date

Release Date

Dec 18, 2017

Expiration Date

Dec 18, 2018

Everything a clinician needs to know about DNA repair and PARP inhibition
Thomas Helleday, PhD

A new string to the bow in the treatment of advanced ovarian cancer
Bradley J. Monk, MD, FACS, FACOG

Clinical application of PARP inhibitors: Proactive management of adverse events
Rebecca Kristeleit, MD, PhD

prIME Points™
Nicoletta Colombo, MD


  • Nicoletta Colombo, MD, PhDUniversity of Milan–Bicocca
    European Institute of Oncology
    Milan, Italy
  • Thomas Helleday, PhDKarolinska Institute
    Stockholm, Sweden
  • Rebecca Kristeleit, MD, PhDUCL Cancer Institute
    University College London
    London, United Kingdom
  • Bradley J. Monk, MD, FACS, FACOGArizona Oncology (US Oncology Network)
    University of Arizona College of Medicine-Phoenix
    Creighton University School of Medicine at St Joseph's Hospital
    Phoenix, Arizona, United States

This educational activity is designed for oncologists, gynecologists, and other healthcare professionals interested and/or involved in the use of PARP inhibitors for the treatment of patients with ovarian cancer.

After successful completion of this educational activity, participants should be able to:

  • Describe current and emerging biomarkers that assess genomic instability and evaluate defects in DNA repair
  • Evaluate emerging clinical data and ongoing trials involving PARP inhibition for patients with BRCA 1/2 mutant and wildtype ovarian cancer
  • Assess the adverse events associated with PARP inhibition for ovarian cancer and how best to ensure long-term adherence to PARP inhibitors

This educational activity is supported by a grant from Clovis Oncology, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Insights on PARP Inhibition and Ovarian Cancer - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This enduring activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online post-test with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Colombo has disclosed that she has received consulting fees from Advaxis, Amgen, AstraZeneca, Clovis, Merck Sharp & Dohme, Pfizer Inc, PharmaMar, Roche, and Tesaro. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Helleday is chairman of the Helleday Foundation that is sponsoring clinical trials with DNA repair inhibitors, and he holds intellectual property rights as he is the inventor of novel treatments in the area of DNA repair. Dr Helleday is a shareholder in Oxcia AB, and he is receiving milestones and royalty from PARP inhibitors (eg, lynparza, talazoparib, veliparib). He is the sole original inventor of PARP inhibitors in BRCA cancers and sole inventor on the critical patent. Dr Helleday receives royalties from the University of Sheffield who has a contract with KuDOS, bought by AZ who has sublicensed to Clovis, Biomarin (Medivation and now Pfizer), and Abbvie. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kristeleit has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Monk has disclosed that he has performed contracted research for Amgen, Array, Genentech, Janssen/Johnson & Johnson, Lilly, Morphotek, and Tesaro. He has also received consulting fees from Advaxis, Amgen, AstraZeneca, Bayer, Clovis, Gradalis, Insys, Mateon, Merck, Pfizer, PPD, Roche/Genentech, and Tesaro. He has also received fees for non-CME services received directly from commercial interest or their agents from AstraZeneca, Janssen/Johnson & Johnson, Myriad, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – contracted research for Amgen and Bayer
  • Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.